IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2022 | Overweight → Neutral | JP Morgan | |
| 3/7/2022 | $11.00 → $10.00 | Equal-Weight | Morgan Stanley |
| 2/15/2022 | $24.00 → $11.00 | Equal-Weight | Morgan Stanley |
| 11/15/2021 | $26.00 → $24.00 | Equal-Weight | Morgan Stanley |
| 8/9/2021 | Outperform | Cowen | |
| 8/9/2021 | $26.00 | Equal-Weight | Morgan Stanley |
| 8/9/2021 | $28.00 | Buy | Stifel |
| 8/9/2021 | $30.00 | Overweight | JP Morgan |
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2024 Healthcare Conference. Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 30-minute question-and-answer session with the host analyst on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout Achieved inflection in gross margins to positive 8%, representing a significant company milestone and a 35 percentage point improvement compared to the third quarter of 2023Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 2
LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024. In conjunction with the release, the Company's management team will host a webcast conference call beginning at 9:00 a.m. ET on Friday, November 1, 2024. The live audio webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. A
LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, in New York City. Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 35-minute question-and-answer session with the host analyst at 7:00 a.m. Eastern Time. A live webcast of the session will be available on the Rapid M
Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023150th Growth Direct® system placed with an existing top 15 global pharma customer First Growth Direct Rapid Sterility system placed with an existing top 10 global pharma customerGross margin improved by 35 percentage points compared to the second quarter of 2023, and by 24 percentage points compared to the first quarter of 2024Announces operational efficiency program that is expected to enable the Company to achieve positive cash flow without additional financingReaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compa
LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2024 financial results prior to the market open on Friday, August 2, 2024. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, August 2, 2024. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid Micro Biosy
Reports first quarter 2024 total revenue of $5.6 million, representing growth of 11% compared to first quarter 2023 Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023 LOWELL, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2024. Recent Highlights First quarter total revenue (combined product a
LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2024 financial results prior to the market open on Friday, May 3, 2024. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 3, 2024. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid Micro Biosyst
LOWELL, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will exhibit at the 2024 Parenteral Drug Association ("PDA") Annual Meeting from March 25 – 27, 2024 in Long Beach, CA. This year's PDA Annual Meeting is at the core of the inaugural PDA Week that features many events including training, roundtables, presentations and tours that address the opportunities and challenges most relevant to the future of pharmaceutical microbiology
LOWELL, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the virtual KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a question-and-answer session with the host analyst on Tuesday, March 19, 2024, at 12:00 p.m. Eastern Time. This presentation time has been updated from the Company's previously
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
ARS - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
DEFA14A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral
Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $10.00 from $11.00 previously
Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $11.00 from $24.00 previously
Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $24.00 from $26.00 previously
Cowen initiated coverage of Rapid Micro Biosystems with a rating of Outperform
Morgan Stanley initiated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $26.00
Stifel initiated coverage of Rapid Micro Biosystems with a rating of Buy and set a new price target of $28.00
JP Morgan initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $30.00
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout Achieved inflection in gross margins to positive 8%, representing a significant company milestone and a 35 percentage point improvement compared to the third quarter of 2023Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 2
LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024. In conjunction with the release, the Company's management team will host a webcast conference call beginning at 9:00 a.m. ET on Friday, November 1, 2024. The live audio webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. A
Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023150th Growth Direct® system placed with an existing top 15 global pharma customer First Growth Direct Rapid Sterility system placed with an existing top 10 global pharma customerGross margin improved by 35 percentage points compared to the second quarter of 2023, and by 24 percentage points compared to the first quarter of 2024Announces operational efficiency program that is expected to enable the Company to achieve positive cash flow without additional financingReaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compa
LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2024 financial results prior to the market open on Friday, August 2, 2024. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, August 2, 2024. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid Micro Biosy
Reports first quarter 2024 total revenue of $5.6 million, representing growth of 11% compared to first quarter 2023 Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023 LOWELL, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2024. Recent Highlights First quarter total revenue (combined product a
LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2024 financial results prior to the market open on Friday, May 3, 2024. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 3, 2024. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid Micro Biosyst
Reports fourth quarter 2023 total revenue of $6.3 million, representing 45% growth compared to fourth quarter 2022 Reports 2023 revenue of $22.5 million, representing 31% growth compared to 2022 Delivered 2023 recurring revenue of $13.5 million, representing 23% growth compared to 2022 Provides 2024 revenue guidance of at least $27.0 million, representing at least 20% growth compared to 2023 LOWELL, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, toda
LOWELL, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2023 financial results prior to the market open on Friday, March 1, 2024. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, March 1, 2024. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid
Reports third quarter 2023 total revenue of $6.1 million, representing growth of 30% compared to third quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30% compared to full year 2022 LOWELL, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the third quarter ended September 30, 2023. Recent Highlights Third quarter total revenue (combined
LOWELL, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2023 financial results prior to the market open on Friday, November 3, 2023. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, November 3, 2023. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid Micr
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13D/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13D - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
Rapid Micro Biosystems (NASDAQ:RPID) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 3.13 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $5.611 million which beat the analyst consensus estimate of $5.500 million by 2.02 percent. This is a 11.44 percent increase over sales of $5.035 million the same period last year.
Shares of Apple Inc. (NASDAQ:AAPL) rose sharply in today's pre-market trading after the company reported better reported better-than-expected results for its second quarter. The company announced a $110-billion stock buyback program and a one-penny-per-share increase in its quarterly dividend. Apple shares jumped 5.9% to $183.24 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Vaxxinity, Inc. (NASDAQ:VAXX) gained 45.8% to $0.1519 in pre-market trading after falling 9% on Thursday. Vaxxinity recently announced its intention to voluntarily delist and deregister its Class A common stock. El Pollo Loco Holdings, Inc. (NASDAQ:LOCO) gained
Companies Reporting Before The Bell • McEwen Mining (NYSE:MUX) is estimated to report quarterly loss at $0.28 per share on revenue of $71.72 million. • PropertyGuru Group (NYSE:PGRU) is estimated to report quarterly loss at $0.02 per share on revenue of $31.70 million. • Plug Power (NASDAQ:PLUG) is projected to report quarterly loss at $0.44 per share on revenue of $236.44 million. • CSI Compressco (NASDAQ:CCLP) is projected to report earnings for its fourth quarter. • EchoStar (NASDAQ:SATS) is likely to report quarterly loss at $0.10 per share on revenue of $3.89 billion. • Rapid Micro Biosystems (NASDAQ:RPID) is expected to report quarterly loss at $0.30 per share on revenue of $6.15
Rapid Micro Biosystems (NASDAQ:RPID) reported its Q4 earnings results on Friday, March 1, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Rapid Micro Biosystems beat estimated earnings by 13.0%, reporting an EPS of $-0.26 versus an estimate of $-0.3. Revenue was up $1.96 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.0 which was followed by a 7.000000000000001% increase in the share price the next day. Here's a look at Rapid Micro Biosystems's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.31 -0.36 -0.36 -0.36 EPS Actual -0.31 -0.33 -0.32 -0.39 Revenue E
Rapid Micro Biosystems (NASDAQ:RPID) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 33.33 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $6.34 million which beat the analyst consensus estimate of $6.15 million by 3.04 percent. This is a 44.88 percent increase over sales of $4.37 million the same period last year.
Rapid Micro Biosystems (NASDAQ:RPID) is set to give its latest quarterly earnings report on Friday, 2024-03-01. Here's what investors need to know before the announcement. Analysts estimate that Rapid Micro Biosystems will report an earnings per share (EPS) of $-0.30. Rapid Micro Biosystems bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company missed EPS by $0.00, which was foll
Gainers Atreca (NASDAQ:BCEL) shares rose 45.6% to $0.34 during Thursday's after-market session. The market value of their outstanding shares is at $13.4 million. Evoke Pharma (NASDAQ:EVOK) shares moved upwards by 16.45% to $0.99. The market value of their outstanding shares is at $3.3 million. INVO Bioscience (NASDAQ:INVO) stock increased by 10.57% to $1.15. The market value of their outstanding shares is at $2.8 million. Avenue Therapeutics (NASDAQ:ATXI) shares rose 9.25% to $0.19. The company's market cap stands at $2.5 million. Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 6.82% to $0.26. The company's market cap stands at $6.7 million. Monopar Therapeutics (NASDAQ:MNPR) s
LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar
LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S
MALVERN, Pa., April 4, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry-leading provider of drug discovery services, today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company's next stage of growth. "We are thrilled to welcome Rich, a seasoned healthcare finance and operations executive, to the Executive Committee of Reaction Biology," said John H. Johnson, Chief Executive Officer and Director of Reaction Biology. "Having managed large, global biopharmaceut
LOWELL, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the appointment of Michael Beaulieu as Vice President, Investor Relations and Corporate Communications. "We are excited to welcome Mike to the Rapid Micro team," said Sean Wirtjes, Chief Financial Officer. "He brings a deep understanding of the healthcare investment community that will be invaluable as we continue to expand our outreach and engagement and increase awareness of our auto
LOWELL, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Inese Lowenstein to its Board of Directors. "We are very excited to welcome Inese, an experienced Life Science business leader in the STEM (science, technology, engineering and mathematics) field to our board of directors," said President and Chief Executive Officer, Robert Spignesi. "She has held leadership positions at Danaher Corporation ("Danaher"), SCIEX, Merck KGaA, and E
LOWELL, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (Rapid Micro), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of veteran life sciences executive Andy Keys to the newly created position of Chief Commercial Officer (CCO). Keys joins Rapid Micro from Quanterix Corporation (Quanterix), where he most recently served as Senior Vice President, Global Commercial Operations. Drawing upon two decades of experience as a biopharmaceutical scientist, commercial leader, and life science